{"id":860349,"date":"2025-06-13T07:22:33","date_gmt":"2025-06-13T11:22:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/"},"modified":"2025-06-13T07:22:33","modified_gmt":"2025-06-13T11:22:33","slug":"arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/","title":{"rendered":"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2013 ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma \u2013<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>\u2013 In combination with small molecule inhibitors, ARV-393 demonstrated enhanced tumor growth inhibition, including tumor regressions, in models of aggressive diffuse large B-cell lymphoma (DLBCL) \u2013 <\/em>\n      <\/p>\n<p>NEW HAVEN, Conn., June  13, 2025  (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical studies of ARV-393, the company\u2019s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI also known as AITL) and PDX models of transformed follicular lymphoma (tFL). In combination with oral small molecule inhibitors (SMIs), ARV-393 demonstrated enhanced antitumor activity, including tumor regressions, in cell line-derived xenograft (CDX) models of high-grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL). The results from these preclinical studies were shared at the European Hematology Association (EHA) 2025 Congress in Milan, Italy.<\/p>\n<p>Key findings from the preclinical studies included:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">Single-agent ARV-393 significantly reduced tumor burden in peripheral blood, bone marrow and spleen in a systemic PDX model of nTFHL-AI derived from a patient who relapsed post chemotherapy. This is potentially the first preclinical evidence of anti-tumor activity with an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model.<\/li>\n<li style=\"margin-bottom:8pt\">ARV-393 monotherapy treatment resulted in robust (\u226595%) tumor growth inhibition (TGI) in two PDX models of tFL.<\/li>\n<li style=\"margin-bottom:8pt\">ARV-393 in combination with 5 classes of SMIs targeting potentially cooperative oncogenic drivers (tazemetostat, palbociclib, everolimus, acalabrutinib, or venetoclax) demonstrated increased TGI in CDX models of HGBCL and aggressive DLBCL compared with the respective monotherapy treatments. Tumor regressions were observed when ARV-393 was combined with tazemetostat, palbociclib, acalabrutinib, or venetoclax.<\/li>\n<li style=\"margin-bottom:8pt\">RNA sequencing studies carried out to further characterize downstream mechanism of action suggested that ARV-393 inhibits tumor cell cycle progression and promotes differentiation, driving antitumor activity and broad combinability in preclinical models.<\/li>\n<\/ul>\n<p>\u201cWe are encouraged by the marked single-agent activity of ARV-393 in PDX models of AITL and transformed follicular lymphoma and by the enhanced antitumor activity of ARV-393 in combination with five classes of small molecule inhibitors in models of aggressive DLBCL,\u201d said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas. \u201cWe believe these preclinical data potentially suggest the broad utility of ARV-393 across non-Hodgkin lymphoma subtypes with unmet need beyond DLBCL and provide a compelling rationale for considering combination strategies including chemotherapy-free approaches as we work to bring forward new therapeutic options for adult patients with lymphoma.\u201d<\/p>\n<p>A Phase 1 study of ARV-393 is enrolling adult patients with relapsed\/refractory non-Hodgkin lymphoma, including DLBCL and nTFHL-Al (AITL) (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3hcU2Eblo9UgM7sOSVVUqLk0apLlrBQOE4a8rs48rsZ-INA9T2MzTLkDxGCpdwJENykWYqcemdDrSHGK7exEPtW1FW5ecbJvXJbRVDzIonBfV9fgFFLFhbVSfOo-GPS0WTJmV6FJgBAKah-SbDWPcXiKa6qosU5ArpQ1_s9JZXz9rYRMG7dOC-aO4NCOBh3eNuF_ZdP0pwbDN_emG0KrpZIho6mjYkpjPDAhpCC3AEEQtEtrl1F6DE1xN1IzXTuoQ2GtSKRzQBAZO_ni-rUcMtsVMMS9toz2C7SvI_W_2HU8fGFCRqDfooReCiEsgPpCXxO1FGDThfRWg2PxF6bVQA==\" rel=\"nofollow\" target=\"_blank\"><strong>NCT06393738<\/strong><\/a>).<\/p>\n<p>\n        <strong>Additional detail on the ARV-393 data presentation at the EHA 2025 Congress:<\/strong>\n      <\/p>\n<p>\n        <strong>Poster Title:<\/strong>\u202fARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular Lymphoma<\/p>\n<p>\n        <strong>Abstract:\u202f<\/strong>PF1000\u00a0<br \/><strong>Session Title:<\/strong>\u202fLymphoma biology &amp; translational research\u202f<strong>\u00a0<\/strong><br \/><strong>Date:\u202fThursday, June 13, 2025<\/strong><br \/><strong>Time:<\/strong>\u202f6:30-7:30 pm CEST<strong>\u00a0<\/strong><\/p>\n<p>\n        <strong>About ARV-393<\/strong><br \/>\n        <br \/>ARV-393 is an investigational orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B-cell lymphomas. The BCL6 protein facilitates B cell tolerance of rapid proliferation and somatic gene recombination via repressing cell cycle checkpoints, terminal differentiation, apoptosis, and the DNA damage response. PROTAC-mediated degradation has the potential to address the traditional undruggable nature of BCL6. ARV-393 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed\/refractory non-Hodgkin lymphoma.<\/p>\n<p>\n        <strong>About Arvinas<\/strong><br \/>\n        <br \/>Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body\u2019s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+\/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed\/refractory non-Hodgkin lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a5l_P7lXeu17vQIUIVW4VWYp0Iw3eGxqG9lBPIFkzc59kproMW0TvMyF78vH482Ixi7tu_aqvIPspQurYywQ4HYzVbphuC6Ja0jboJmHGOcVPTHPpnP4bqeQTs5quT4S-D-9yD46gjWkOm3V4kDkef8zw7AURCBDMvpR2CiBhP-38RF9A6EKep8MCHDs_-XnaIPE6kfQYyhaMfwnm1vfq4VGmCx9uqz8iMCdrB0tEmw_po_5O061XLh8rxHoSktkNbkXHZfG0sqi2ffTe6_50UCPfPSfKBAY74bikbHpdXCLNl366ULJQ_jNEReiePMcxn-IVLqW9hAqVIUB2OLlp6gKRZyxqSqcFsXSSL84eu0twrkRflbCgg5Bq9yFX0X5VFzI-B4umm2I-nTu0ZEgPAFhuA0-ne6GJBUuBTl6N8MQg_BG0HcPyW22LqB20WEZ\" rel=\"nofollow\" target=\"_blank\"><strong>www.arvinas.com<\/strong><\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eigSJz9iCvRlb3w7_TCuKnTNrm3rSOCfvVPmtPYQbG7yUUtASRAfwMSCHCDJi0rZWH_mhTKIIYIqn8A4JPULe99HHsUbEATHHDDqLoBJVmwQpn38QKf-KhjrLPMY46aRvdGulMNYFJoytn2dbo391GCyfwO3w1od-ck3WzpH0ZyjGLsUiep6cCWo80jMe5gVpQA7SHHdwguwJaET3Ew-5kL3pH4_tTi0h8FYkg_luGRjXuYQ5YBidmLAy3hCVhG8yxIBu1_CLvO3Gs5rxzm7PwDV0WU-1IIRWTIPZDk24mA7MApQ8CUke5Jq1tmu02dMjh9rFfwSV-GTCelox6Mpso0hknpbejIgK5s7Zk506xJmnvIAw_4cwVJWXEoFxzcj8ToPgQAA-BGJtuIxEE3PFlXMf6tc9fn_UgejdyrjyLeaQ-kNOHlrymjw7UwXu9D7C7ewSMeKzazUq_9ps8AVU8XTm7DcJuNR7pUKJh5ZBu_8VWmtLBbUo3pFChJG0xWU_E9y_-1nxjpbjhQdLAfm6RS4UYWIwpsfEPmcQgrpbi1gJjXyOmQV2zRQnJm7i5zjGNzKW4uyao_oRuQwHmcvdj0ep3I2LS_uPJyfyazrAH6BSLy36oP6BBWJ11jtbzgq_VaiiSM8w-57PpFBZpK7tJP6LbCGeTQaFlGS1B9V89jasuQNYR1eohzOg4XnTnfBEDskjd_q46NjoyVbKfu594CbSgCwDdwesFmLHUmW8FwQ9Npnfp7NwXPlL3DAaoeID668R1iR3-SjyKL0Hbr80BwamzlARPVGlFqa72U3K_1lNgYrT6wS9g70NriayzDnuBinKZw46v2QgWLwtcTl-Dyi_8H80JElkB_-YOe0DOvccAYB8zcZbg-QyhZJZY8FnuRqqipkOuWuWZalH-XrrJKHQi6ZqRnd0z1Razyz_tj29EFbDoPcOIuiRVMO3zAtaL5x9cS3KWSpN9NX7ViohYTs-F3mqa-7x_zvZ_GXQU-8tK_3MvkyJ3kbZqr0MNtOt8A0L3jQBiEMXIxPM5yyrw==\" rel=\"nofollow\" target=\"_blank\"><strong>LinkedIn<\/strong><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iXtpuYiCeMinhTzrLl7ZI6p1PDFyUhVITBJjltlFCs9pbMeE4TZ6pSieMaraQ_PWnf53cR4pQ51Jcw6UbvyKxvJrrv9JwtGZe_N05yjVy_OrK_HTXNdynGLxVHKISMGFvMF7EO-qw7V1dceKjn97hYxsMYo3rgJdIQZSbnWIC1c8BrAAw79OuHmQeMUHSOLNWB8YHlFrzqs_E6B6wH5oEGLGd5opVIs8xYB6EzShxtikCvPcpVDKGap4b0Pie3Z-DZdLLn5qcW4S1eojXtStOE5SJplOYlQkcn4VHqml5uQS8zDKTHChdCJL9cizyhFt3S5OUx6iWngCMkevXYMMDalgpoU0KhLyteuWXzWdqLPbJar8GHy5Nl_36kfAG3E2cneDSNghDFqAnb0X9J48ZnUr59PuDHX6NbAmPgcutgMhpgPGFjPj7HBqATPNPS23koAtnbim_xRVP3DDPU9oWXLP5kmvQQZ2-1b3xZoUmsArt4eN4AHxgFH5XxCt8mUaa3x7YgBHSHs1J9dfFLPzfGC2fK-_XaUo0p7Wc3tqJAYG0I7TNCXBjABlmU12B_63hVmJG4Xc3TMLlhPeDO2JXZ0QpcZh7DF80aSw2_GNkHQsqLGXs6mNodDh0EB4c57PupmZEyL1IqCQ8_KTrLYtq_-R_-toDFLLwy-AhbwUYdyzsdRojeRlHA35vMfnVv1Tv9z07X1rIpxpMNHZn2hITw6xNpJgLZRq35PDW9c2EYE3Zt-apw_qTGCKnzZj1hbx-dlDJcIIioy0NgFN8pcEF722Mr0X9PUUSU5N53wXDdhgbvQHPzsUCzBxo2n7453d9h9sFYu6-tXWaAtWA2V8EY46EHFwTCMlsze2EeJEL2WYGWziYnYyPVewYkx9m5eOb1IYShkWDn49WsRqoipUqN08ziydG0oer1vlqISCNP8=\" rel=\"nofollow\" target=\"_blank\"><strong>X<\/strong><\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: whether this data shows the first preclinical evidence of anti-tumor activity with an efficacious B-cell lymphoma 6 protein-targeted small-molecule degrader in a human nodal T-follicular helper cell lymphoma, angioimmunoblastic-type model; whether ARV-393 inhibits tumor cell cycle progression and promotes differentiation, driving antitumor activity and broad combinability in preclinical models; that ARV-393 preclinical data potentially suggest the broad utility of ARV-393 across non-Hodgkin lymphoma subtypes with unmet need beyond diffuse large B-cell lymphoma; that ARV-393 preclinical data provide a compelling rationale for considering combination strategies including chemotherapy-free approaches; and whether Arvinas will bring forward new therapeutic options for adult patients with lymphoma and the timing thereof. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas\u2019 strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201ctarget,\u201d \u201cgoal,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201clook forward,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. <br \/>\u00a0\u00a0 <br \/>Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for ARV-393 and its other product candidates; other risks associated with drug development, including unexpected costs or delays; that positive data from preclinical or early clinical studies of Arvinas\u2019 product candidates are not necessarily predictive of the results of later clinical studies and any future clinical trials of Arvinas\u2019 product candidates; Arvinas\u2019 ability to protect its intellectual property portfolio; Arvinas\u2019 reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas\u2019 cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the \u201cRisk Factors\u201d section of Arvinas\u2019 Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas\u2019 current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas\u2019 views as of any date subsequent to the date of this release.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Jeff Boyle<br \/>+1 (347) 247-5089<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gAWMMg4_I_qo2anHfi18eN-i9y8Es-Ndy2HD5l17uX8iIJxD7nm2cS8FEFNmx5lFwM8qzsQqzKCMCssNgWSl7H4qrJDbgYFgOF9yuRD-7EaN9ewQ-z5oYZ94MlGVlFInt26NoMQ0tyRHQ7XMihHEZtTSJjiwH-lhdPSM2ohr7ySb-t4xEpEbqoyJa089eo1B7q-UXIdxkBZn2XUhoKOY9hY5CEJwaxTg4FySy_1hpTu6UV6n-C9x2QibGrqqvRsZWl3vVpwDkyVIsEglF90rpg==\" rel=\"nofollow\" target=\"_blank\"><strong>Jeff.Boyle@arvinas.com<\/strong><\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Kirsten Owens<br \/>+1 (203) 584-0307<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2v15C1rGcVeTq31G-ictgdjY9E8wwGdQ56U558eBrkey8rBzqA0AUc6Y-WAqU6C4RbszXa3-BuPkQS1ICmJWvvIWeHSOAd1o1O9AhhOVWtCOwd3I00i7M2DI9q2ROSDPLW7jYFO2al_bH_fA8ZtSELdS4j9lAtXeMS6yhlxQmADCRAeGRyYvjAifc8OH_ME2Uacr9Ct1jD7JojdlakTzcB66JYa-uSfIOdzFHJqva-eyiF00fjtfBkNoe5SAHOUokI901EkqB3H8R_aHWno2WQ-GyQPZS50_v_tUT8G9dnY=\" rel=\"nofollow\" target=\"_blank\"><strong>Kirsten.Owens@arvinas.com<\/strong><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTQ4N2E1ZjEtNjRlOS00ZDdmLWJiMzEtMmI4NDE0YzM4NmZjLTExMzM2NDctMjAyNS0wNi0xMy1lbg==\/tiny\/Arvinas-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma \u2013 \u2013 In combination with small molecule inhibitors, ARV-393 demonstrated enhanced tumor growth inhibition, including tumor regressions, in models of aggressive diffuse large B-cell lymphoma (DLBCL) \u2013 NEW HAVEN, Conn., June 13, 2025 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical studies of ARV-393, the company\u2019s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-860349","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma \u2013 \u2013 In combination with small molecule inhibitors, ARV-393 demonstrated enhanced tumor growth inhibition, including tumor regressions, in models of aggressive diffuse large B-cell lymphoma (DLBCL) \u2013 NEW HAVEN, Conn., June 13, 2025 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical studies of ARV-393, the company\u2019s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in &hellip; Continue reading &quot;Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-13T11:22:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress\",\"datePublished\":\"2025-06-13T11:22:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/\"},\"wordCount\":1237,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/\",\"name\":\"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=\",\"datePublished\":\"2025-06-13T11:22:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/","og_locale":"en_US","og_type":"article","og_title":"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - Market Newsdesk","og_description":"\u2013 ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma \u2013 \u2013 In combination with small molecule inhibitors, ARV-393 demonstrated enhanced tumor growth inhibition, including tumor regressions, in models of aggressive diffuse large B-cell lymphoma (DLBCL) \u2013 NEW HAVEN, Conn., June 13, 2025 (GLOBE NEWSWIRE) &#8212; Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical studies of ARV-393, the company\u2019s investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in &hellip; Continue reading \"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-13T11:22:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress","datePublished":"2025-06-13T11:22:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/"},"wordCount":1237,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/","name":"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=","datePublished":"2025-06-13T11:22:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODE1OCM2OTg5NDk0IzIxMjIwNzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arvinas-presents-preclinical-data-for-protac-bcl6-degrader-arv-393-at-the-european-hematology-association-2025-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=860349"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860349\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=860349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=860349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=860349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}